Top

Published in:

01-08-2006 | Original Research Article

Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone

Authors: Dr Richard S. Geary, Joann D. Bradley, Tanya Watanabe, Younggil Kwon, Mark Wedel, Jan J. van Lier, Andrè A. van Vliet

Published in: Clinical Pharmacokinetics | Issue 8/2006

Abstract

Background

ISIS 113715 is a 20-mer phosphorothioate antisense oligonucleotide (ASO) that is complementary to the protein tyrosine phosphatase 1B (PTP-1B) messenger RNA and subsequently reduces translation of the PTP-1B protein, a negative regulator of insulin receptor. ISIS 113715 is currently being studied in early phase II clinical studies to determine its ability to improve or restore insulin receptor sensitivity in patients with type 2 diabetes mellitus. Future work will investigate the combination of ISIS 113715 with antidiabetic compounds.

Methods

In vitro ultrafiltration human plasma protein binding displacement studies and a phase I clinical study were used to characterise the potential for pharmacokinetic interaction of ISIS 113715 and three marketed oral antidiabetic agents. ISIS 113715 was co-incubated with glipizide and rosiglitazone in whole human plasma and tested for increased free drug concentrations. In a phase I clinical study, 23 healthy volunteers received a single oral dose of an antidiabetic compound (either metformin, glipizide or rosiglitazone) both alone and together with subcutaneous ISIS 113715 200mg in a sequential crossover design. A comparative pharmacokinetic analysis was performed to determine if there were any effects that resulted from coadministration of ISIS 113715 with these antidiabetic compounds.

Results

In vitro human plasma protein binding displacement studies showed only minor effects on rosiglitazone and no effect on glipizide when co-incubated with ISIS 113715. The results of the phase I clinical study further indicate that there were no measurable changes in glipizide (5mg), metformin (500mg) or rosiglitazone (2mg) exposure parameters, maximum plasma concentration and the area under the concentration-time curve, or pharmacokinetic parameter, elimination half-life when coadministered with ISIS 113715. Furthermore, there was no effect of ISIS 113715, administered in combination with metformin, on the urinary excretion of metformin. Conversely, there were no observed alterations in ISIS 113715 pharmacokinetics when administered in combination with any of the oral antidiabetic compounds.

Conclusion

These data provide evidence that ISIS 113715 exhibits no clinically relevant pharmacokinetic interactions on the disposition and clearance of the oral antidiabetic drugs. The results of these studies support further study of ISIS 113715 in combination with antidiabetic compounds.

Frangioni JV, Beahm PH, Shifrin V, et al. The nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 1992; 68: 545–60PubMedCrossRef

Kenner KA, Anyanwu E, Olefsky JM, et al. Protein-tyrosine phosphatase 1B is a negative regulator of insulin- and insulin-like growth factor-I-stimulated signaling. J Biol Chem 1996; 271: 19810–6PubMedCrossRef

Rondinone CM, Trevillyan JM, Clampit J, et al. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 2002; 51: 2405–11PubMedCrossRef

Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99: 11357–162PubMedCrossRef

Geary RS, Leeds JM, Shanahan W, et al. Sequence independent plasma and tissue pharmacokinetics for 3 antisense phosphorothioate oligonucleotides: mouse to man. Seattle (WA): American Association of Pharmaceutical Scientists, 1996: S–395

Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2’-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419–28PubMedCrossRef

Geary RS, Ushiro-Watanabe T, Truong L, et al. Pharmacokinetic properties of 2’-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296: 890–7PubMed

Yu RZ, Geary RS, Monteith DK, et al. Tissue disposition of a 2’-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci 2004; 93: 48–59PubMedCrossRef

Grundy JS, Yu RZ, Geary RS. Comparative single-dose disposition of radiolabeled ISIS 104838 and ISIS 113715 in rat. Annual Meeting of Pharmaceutical Scientists; 2002 Nov 10–14; Toronto

10.

Gaus HJ, Owens SR, Winniman M, et al. On-line HPLC electrospray mass spectrometry of phosphorothioate oligonucleotide metabolites. Anal Chem 1997; 69: 313–9PubMedCrossRef

11.

Phillips JA, Craig SJ, Bayley D, et al. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligode-oxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 1997; 54: 657–68PubMedCrossRef

12.

Sewell LK, Geary RS, Baker BF, et al. Phase I trial of ISIS 104838, a 2’-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002; 303: 1334–43PubMedCrossRef

13.

Sambrook J, Maniatis T, Fritsche EF. Molecular cloning: a laboratory manual. 1st ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1982

14.

BMS Company. Glucophage® (metformin hydrochloride tablets) prescribing information. Princeton (NJ): 1999

15.

Yu RZ, Geary RS, Levin AA. Application of novel quantitative bioanalytical methods for pharmacokinetic and pharmacokinetic/pharmacodynamic assesments of antisense oligonucleoutides. Curr Opin Drug Discov Devel 2004; 7: 195–203PubMed

16.

Yu RZ, Baer B, Chappel A, et al. Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 2002; 304:19–25PubMedCrossRef

17.

Guidance for industry. In vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labeling. US Department of Health and Human Services, FDA, 1999

18.

Ovalle F, Bell DS. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998; 4: 146–7PubMed

19.

Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract 2002; 8: 271–5PubMed

20.

Donahue SR, Turner KC, Patel S. Pharmacokinetics and pharmacodynamics of glyburide/metformin tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes. Clin Pharmacokinet 2002; 41: 1301–9PubMedCrossRef

21.

Cox PJ, Ryan DA, Hollis FJ, et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772–80PubMed

22.

Balant L, Fabre J, Zahnd GR. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 1975; 8: 63–9PubMedCrossRef

23.

Hruska MW, Amico JA, Langaee TY, et al. The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Br J Clin Pharmacol 2005; 59: 70–9PubMedCrossRef

24.

Adjei AA, Dy GK, Erlichman C, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003; 9: 115–23PubMed

25.

Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase I/II study of LY900003, an Antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 6086–93PubMedCrossRef

26.

Motl SE. LY900003: a novel compound for the treatment of non-small cell lung cancer. Cancer Ther 2003; 1: 237–44

27.

Geary RS, Leeds JM, Fitchett J, et al. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab Dispos 1997; 25: 1272–81PubMed

28.

Glover JM, Leeds JM, Mant TG, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997; 282: 1173–80PubMed

29.

Brown DA, Kang SH, Gryaznov SM, et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 1994; 269: 26801–5PubMed

30.

Watanabe T, Geary RA, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISI 2303). Oligonuceotides 2006; 16: 169–80CrossRef

Title: Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone
Authors: Dr Richard S. Geary
Joann D. Bradley
Tanya Watanabe
Younggil Kwon
Mark Wedel
Jan J. van Lier
Andrè A. van Vliet
Publication date: 01-08-2006
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 8/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/00003088-200645080-00003

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Lack of Pharmacokinetic Interaction for ISIS 113715, a 2′-0-Methoxyethyl Modified Antisense Oligonucleotide Targeting Protein Tyrosine Phosphatase 1B Messenger RNA, with Oral Antidiabetic Compounds Metformin, Glipizide or Rosiglitazone

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2006

The Author’s Reply

Comparison of Equivalent Doses of Fentanyl Buccal Tablets and Arteriovenous Differences in Fentanyl Pharmacokinetics

Chronopharmacokinetics of Ciclosporin and Tacrolimus

Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

Antibacterial Dosing in Intensive Care

Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects